Gotaro Kojima1. 1. Japan Green Medical Centre, 10 Throgmorton Avenue, London, EC2N 2DL, UK. gotarokojima@yahoo.co.jp.
Abstract
PURPOSE: The purpose of this study is to perform a systematic review and meta-analysis on prevalence of frailty among patients with end-stage renal disease (ESRD). ESRD is associated with malnutrition, chronic inflammation, acidemia, impaired hormonal changes, and low physical activity, all of which can directly and indirectly contribute to the development of frailty. Coexistence of ESRD and frailty has been shown to increase risks of adverse health outcomes. Given potential reversibility of frailty, it is important to examine frailty status in this high-risk population. METHODS: Three databases (EMBASE, Medline, and CINAHL) were systematically searched for studies providing cross-sectional data of prevalence of frailty defined by cardiovascular health study (CHS) criteria among ESRD patients. Meta-analysis calculated pooled prevalence of frailty according to modifications of CHS criteria. RESULTS: Of 837 studies identified through the systematic review, seven studies were included. Three studies used both objectively measured and self-reported CHS criteria, and two studies each used only either criteria. Pooled prevalence of frailty was 36.8% (five studies: 95% CI = 29.9-44.1%, I 2 = 82.6%, p < 0.001) and 67.0% (five studies: 95% CI = 58.7-74.7%, I 2 = 96.5%, p < 0.001) according to the objectively measured and self-reported CHS criteria, respectively. CONCLUSIONS: More than one-third of ESRD patients were frail based on the objectively measured CHS criteria, and that prevalence of frailty almost doubled with the CHS criteria substituting self-reported physical function questionnaire score for objective measurements. Given substantial difference in prevalence of frailty depending on the modifications to CHS criteria, this information should be taken into account when evaluating frailty status among ESRD population.
PURPOSE: The purpose of this study is to perform a systematic review and meta-analysis on prevalence of frailty among patients with end-stage renal disease (ESRD). ESRD is associated with malnutrition, chronic inflammation, acidemia, impaired hormonal changes, and low physical activity, all of which can directly and indirectly contribute to the development of frailty. Coexistence of ESRD and frailty has been shown to increase risks of adverse health outcomes. Given potential reversibility of frailty, it is important to examine frailty status in this high-risk population. METHODS: Three databases (EMBASE, Medline, and CINAHL) were systematically searched for studies providing cross-sectional data of prevalence of frailty defined by cardiovascular health study (CHS) criteria among ESRDpatients. Meta-analysis calculated pooled prevalence of frailty according to modifications of CHS criteria. RESULTS: Of 837 studies identified through the systematic review, seven studies were included. Three studies used both objectively measured and self-reported CHS criteria, and two studies each used only either criteria. Pooled prevalence of frailty was 36.8% (five studies: 95% CI = 29.9-44.1%, I 2 = 82.6%, p < 0.001) and 67.0% (five studies: 95% CI = 58.7-74.7%, I 2 = 96.5%, p < 0.001) according to the objectively measured and self-reported CHS criteria, respectively. CONCLUSIONS: More than one-third of ESRDpatients were frail based on the objectively measured CHS criteria, and that prevalence of frailty almost doubled with the CHS criteria substituting self-reported physical function questionnaire score for objective measurements. Given substantial difference in prevalence of frailty depending on the modifications to CHS criteria, this information should be taken into account when evaluating frailty status among ESRD population.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Talal A Alfaadhel; Steven D Soroka; Bryce A Kiberd; David Landry; Paige Moorhouse; Karthik K Tennankore Journal: Clin J Am Soc Nephrol Date: 2015-03-04 Impact factor: 8.237
Authors: Mara A McAdams-DeMarco; Jingwen Tan; Megan L Salter; Alden Gross; Lucy A Meoni; Bernard G Jaar; Wen-Hong Linda Kao; Rulan S Parekh; Dorry L Segev; Stephen M Sozio Journal: Clin J Am Soc Nephrol Date: 2015-11-16 Impact factor: 8.237
Authors: Kirsten L Johansen; Lorien S Dalrymple; David Glidden; Cynthia Delgado; George A Kaysen; Barbara Grimes; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2016-01-20 Impact factor: 8.237
Authors: Jonathan Myers; Khin N Chan; Yu Chen; Yiming Lit; Payam Massaband; B Jenny Kiratli; Jane C Tan; Ralph Rabkin Journal: Aging Clin Exp Res Date: 2021-03-08 Impact factor: 3.636
Authors: Evelien E Quint; Donika Zogaj; Louise B D Banning; Stan Benjamens; Coby Annema; Stephan J L Bakker; Gertrude J Nieuwenhuijs-Moeke; Dorry L Segev; Mara A McAdams-DeMarco; Robert A Pol Journal: Transplant Direct Date: 2021-05-18
Authors: Sean Prescott; Jamie P Traynor; Ilona Shilliday; Tobia Zanotto; Robert Rush; Thomas H Mercer Journal: BMC Nephrol Date: 2020-06-16 Impact factor: 2.388